Neuroinflammation In Parkinson'S Disease represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
Pathological alpha-synuclein aggregates act as Damage-Associated Molecular Patterns (DAMPs) that activate innate immune responses:
| Phenotype | Markers | Secreted Factors | Function |
|---|---|---|---|
| M1 (Classical) | CD16, CD32, CD86, iNOS | TNF-α, IL-1β, IL-6, ROS | Pro-inflammatory, cytotoxic |
| M2 (Alternative) | CD206, Arg1, YM1, Fizz1 | IL-4, IL-10, BDNF, IGF-1 | Anti-inflammatory, neuroprotective |
In PD, microglia predominantly adopt the M1 phenotype, contributing to chronic neuroinflammation [2].
| Cytokine | Source | Effect in PD | Therapeutic Target |
|---|---|---|---|
| TNF-α | Microglia, astrocytes | Neuronal apoptosis, BBB disruption | Etanercept, Infliximab |
| IL-1β | Microglia | Promotes alpha-syn aggregation | Anakinra, Canakinumab |
| IL-6 | Microglia, astrocytes | Neurotoxicity, gliosis | Tocilizumab |
| IFN-γ | T cells, NK cells | Microglial priming | Anti-IFN-γ antibodies |
| Chemokine | Receptor | Role in PD |
|---|---|---|
| CXCL12 (SDF-1) | CXCR4 | Microglial recruitment |
| CCL2 (MCP-1) | CCR2 | Monocyte infiltration |
| CCL3 (MIP-1α) | CCR1/5 | Neuroinflammation amplification |
The NLRP3 inflammasome is a key driver of neuroinflammation in PD:
| Gene | Function | Effect on Neuroinflammation |
|---|---|---|
| LRRK2 | Kinase | Enhances microglial activation |
| GBA | Lysosomal enzyme | Impairs autophagy, increases inflammation |
| TREM2 | Microglial receptor | Alters microglial response |
| CD33 | Immune receptor | Increases inflammation |
| HLA-DRB1 | MHC class II | Antigen presentation |
LRRK2 mutations (G2019S, R1441C/G/H) enhance microglial activation:
Neuroinflammation contributes to BBB breakdown in PD:
| Target | Drug Class | Examples | Status |
|---|---|---|---|
| NLRP3 | Small molecule inhibitors | MCC950, Dapansutrile | Preclinical |
| IL-1β | IL-1 receptor antagonist | Anakinra | Phase II |
| TNF-α | Monoclonal antibodies | Etanercept | Phase II |
| COX-2 | NSAIDs | Ibuprofen, Celecobex | Observational |
| CSF1R | Receptor antagonists | PLX3397 | Phase I |
| Biomarker | Sample | Level in PD |
|---|---|---|
| TNF-α | CSF, plasma | Elevated |
| IL-1β | CSF, plasma | Elevated |
| IL-6 | CSF, plasma | Elevated |
| NfL | Plasma | Elevated |
| YKL-40 | CSF | Elevated |
| sTREM2 | CSF | Variable |
| Pathway | Interaction |
|---|---|
| Alpha-synuclein aggregation | Triggers microglial activation; spread via neuroinflammation |
| Mitochondrial dysfunction | Source of ROS; activates NLRP3 |
| GBA/lysosomal pathway | Impairs autophagy; increases inflammatory burden |
| Oxidative stress | Amplifies inflammatory response |
| Excitotoxicity | synergizes with inflammation |
The study of Neuroinflammation In Parkinson'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Hoeijmakers L et al. (2016). Neuroinflammation: A Potential Player in the Link Between Alzheimer's Disease and Parkinson's Disease. CNS Drugs 30(10):967-979.
Liao B et al. (2012). Glial pathology in Parkinson's disease. Prog Brain Res 200:251-263.
Fan Z et al. (2020). Necrosome promotes dopaminergic neurodegeneration in Parkinson's disease via neuroinflammation. Cell Death Differ 27(10):2903-2918.
Russo I et al. (2014). LRRK2 and neuroinflammation: partners in crime in Parkinson's disease? Trends Neurosci 37(5):279-282.
Hirsch EC, Hunot S (2009). Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 8(4):382-397.
McGeer PL et al. (1988). Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38(8):1285-1291.
Block ML, Hong JS (2005). Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 76(2):77-98.
Perry VH et al. (2010). Variance in the location of the substantia nigra. Neuropathol Appl Neurobiol 36(4):355-365.
Wang Q et al. (2015). Neuroinflammation in Parkinson's disease: From pathogenesis to therapy. CNS Neurosci Ther 21(10):753-762.
Brochard V et al. (2009). Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119(1):182-192.
11.文献12: Calco GN et al. (2020). Cellular and Molecular Neuroinflammation in the Parkinson's Disease Brain. J Neurosci Res 98(11):2183-2198.
Tansey MG et al. (2022). Inflammation in Parkinson's disease: Pathogenesis and therapeutic targets. Nat Rev Neurol 18(5):285-305.
Pajares M et al. (2020). Neuroinflammation in the pathogenesis of Parkinson's disease: Role of oxidative stress and therapeutic implications. Redox Biol 37:101688.
Wang B et al. (2021). NLRP3 inflammasome activation in Parkinson's disease: A comprehensive review. Front Aging Neurosci 13:731417.
Kouli A et al. (2018). Parkinson's Disease: Cause and Treatment. Curr Neurol Neurosci Rep 18(8):50.
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 14 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 36%